Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2011

View Archived Issues

Results made available from MENZA trial of enzastaurin

First-in-patient study assesses EMD-525797 in metastatic CRPC

Antifibrinolytic MDCO-2010 safe in first-in-patient trial

Roche to expand HCV portfolio with acquisition of Anadys

Anadys reports interim data from setrobuvir study

Controlled-release phentermine/topiramate formulation shows long-term benefit in obesity

Rib-X Pharmaceuticals describes RX-04 program for developing novel antibiotics

Scientists at Roche present novel farnesoid X receptor agonists

New monoamine reuptake inhibitors synthesized by NeuroSearch

Novo Nordisk prepares new glucagon receptor agonists

Krisani Biosciences patents new pain therapeutics

Novel autotaxin inhibitors designed by Merck KGaA

ABI-007 advances through trial in gastric cancer

Ube and Santen form prostanoid EP2 receptor agonist collaboration

ULURU to out-license European rights to Altrazeal

FDA grants accelerated approval to ApoPharma's Ferriprox

VIVUS resubmits NDA for Qnexa

Dendreon begins enrollment in phase II trial of DN24-02

NeoStem acquires Amorcyte and plans phase II stem cell therapy trial

OTSA-101 clear to enter clinic in France

Infinity Pharmaceuticals provides update on IPI-926 trials

Archimedes Pharma launches Lazanda

TONIX Pharmaceuticals completes reverse merger transaction

ChemoCentryx begins phase II CCX-168 trial

AB Science recruits first patient in phase III masitinib trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...